Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 2/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009589 | 1.00 | TBXAS1 (1.00) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| SCHEMBL607494 | 1.00 | TBXAS1 (1.00) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| SCHEMBL16116694 | 1.00 | TBXAS1 (1.00) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| SCHEMBL744045 | 0.98 | TBXAS1 (1.00) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| Hydrochloric Acid SCHEMBL10768766 | 0.97 | TBXAS1 (1.00) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| SCHEMBL30612524 | 0.93 | TBXAS1 (0.90) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| SCHEMBL1583762 | 0.93 | TBXAS1 (0.90) | TBXAS1MAPTRXFP1HRH1NAPRT | |
| Bicarbonate SCHEMBL9522433 | 0.90 | TBXAS1 (0.81) | TBXAS1MAPTHRH1NAPRTTDP1 | |
| SCHEMBL11063704 | 0.90 | TBXAS1 (0.81) | TBXAS1MAPTRXFP1 | |
| SCHEMBL11068389 | 0.90 | TBXAS1 (0.81) | TBXAS1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0556204-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACE INHIBITOR AND AN INHIBITOR OF THROMBOXANE A2 ACTIVITY FOR TREATING NEPHROPATHIES | FARMITALIA CARLO ERBA S.r.l. (IT) | 1993-08-25 | — | — | EP | claimed |
| WO-1992006713-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACE INHIBITOR AND AN INHIBITOR OF THROMBOXANE A2 ACTIVITY FOR TREATING NEPHROPATHIES | FARMITALIA CARLO ERBA SRL (IT) | 1992-04-30 | — | — | WO | claimed |
| EP-0099685-A2 | (3-Pyridinyl)heteroalkanols and alkanoic acids and esters | THE UPJOHN COMPANY (US) | 1984-02-01 | — | — | EP | claimed |
| US-12409157-B2 | Mitofusin activators and methods of use thereof | DORN, GERALD W., II, DR. | 2025-09-09 | — | — | US | disclosed |
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | DORN, GERALD W., II, DR. | 2024-03-14 | — | — | US | disclosed |
| US-11905525-B2 | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins | MODERNATX, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220047518-A1 | PEG LIPIDS AND USES THEREOF | Moderna TX, Inc. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3853305-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-4891429-A | CHEMICAL INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1990-01-02 | — | — | US | disclosed |
| EP-0299379-A1 | Pentadienamide PAF-antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-18 | — | — | EP | disclosed |
| US-4789745-A | Certain 3-[3-(3-pyridinyloxy)propoxy or propylthio]-acetic acid derivatives which are useful as synthetase inhibitors | THE UPJOHN COMPANY (US) | 1988-12-06 | — | — | US | disclosed |
| US-4696930-A | CARDIOVASCULAR DISORDERS, ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
| EP-0198325-A2 | Substituted aniline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-10-22 | — | — | EP | disclosed |
| US-4551460-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0099685-A2 | (3-Pyridinyl)heteroalkanols and alkanoic acids and esters | THE UPJOHN COMPANY (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0094080-A2 | Pyrido(2,1-b)quinazoline derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | TBXAS1 2074/4885MAPT 500/4885RXFP1 3071/4885 |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | TBXAS1 2074/4885MAPT 500/4885RXFP1 3071/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | TBXAS1 2467/4885MAPT 745/4885RXFP1 3910/4885 |
| US-20220047518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LNPEP | TBXAS1 2313/4885MAPT 1415/4885RXFP1 4222/4885 |
| US-11905525-B2 | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins | CD47, FCGR3B, MSR1 | TBXAS1 3415/4885MAPT 3199/4885RXFP1 3223/4885 |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | TBXAS1 2074/4885MAPT 500/4885RXFP1 3071/4885 |
| US-12409157-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | TBXAS1 2074/4885MAPT 500/4885RXFP1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.